natgillin/translations-raw huggingface dataset:
Ændring i fastende glucoseniveau fra let forhøjet niveau ved baseline (≥ 5,56 - < 7 mmol/l) til højt niveau (≥ 7 mmol/l) var meget almindeligt. 
Changes in fasting glucose from borderline at baseline (≥5.56-<7 mmol/l) to high (≥7 mmol/l) were very common.
Hjælpestof, som behandleren skal være opmærksom på Hver smeltetablet indeholder 142,5 mg lactose, 0,7875 mg saccharose og 6,75 mg aspartam (E951). 
Each orodispersible tablet contains 142.5 mg lactose, 0.7875 mg sucrose and 6.75 mg aspartame (E951).
Urininkontinens Urinretention Vandladningsbev ær11 
Urinary incontinence Urinary retention Urinary hesitation11
Hjælpestof, som behandleren skal være opmærksom på Hver filmovertrukket tablet indeholder 68,9 mg lactose. 
Excipient with known effect Each film-coated tablet contains 68.9 mg lactose.
Observeret for fastende normalt niveau ved baseline (< 5,56 mmol/l), der blev øget til højt niveau (≥ 7 mmol/l). 
4 Observed for fasting normal levels at baseline (<5.56 mmol/l) which increased to high (≥7 mmol/l).
3 Observeret for fastende normalt niveau ved baseline (< 5,17 mmol/l), der blev øget til højt niveau 
3 Observed for fasting normal levels at baseline (<5.17 mmol/l) which increased to high
Almindelige bivirkninger (forekommer hos op til 1 ud af 10 patienter) omfatter ændringer i mængden af visse blodceller, cirkulerende fedtstoffer i blodet samt forbigående forhøjede leverenzymer tidligt i behandlingen; forhøjet sukker i blodet og urinen; forhøjet urinsyre og kreatininkinase i blodet; øget sultfornemmelse; svimmelhed; rastløshed; rysten; unormale bevægelser (dyskinesi); forstoppelse; mundtørhed; hududslæt; tab af styrke; udpræget træthed; væskeophobning, som medfører hævede hænder, ankler eller fødder; feber; ledsmerter og seksuelle problemer såsom nedsat sexlyst (libido) hos mænd og kvinder eller rejsningsbesvær hos mænd. 
Common side effects (may affect up to 1 in 10 people) include changes in the levels of some blood cells, circulating fats and early in treatment, temporary increases in liver enzymes; increases in the level of sugars in the blood and urine; increases in levels of uric acid and creatine phosphokinase in the blood; feeling more hungry; dizziness; restlessness; tremor; unusual movements (dyskinesias); constipation; dry mouth; rash; loss of strength; extreme tiredness; water retention leading to swelling of the hands, ankles or feet; fever; joint pain; and sexual dysfunctions such as decreased libido in males and females or erectile dysfunction in males
Hjælpestof, som behandleren skal være opmærksom på Hver filmovertrukket tablet indeholder 103,3 mg lactose. 
Excipient with known effect Each film-coated tablet contains 103.3 mg lactose.
Hjælpestof, som behandleren skal være opmærksom på Hver smeltetablet indeholder 190,0 mg lactose, 1,05 mg saccharose og 9,0 mg aspartam (E951). 
Each orodispersible tablet contains 190.0 mg lactose, 1.05 mg sucrose and 9.0 mg aspartame (E951).
Ikke almindelige bivirkninger (forekommer hos op til 1 ud af 100 patienter) omfatter overfølsomhed (f.eks. hævelser i mund og hals, kløe, hududslæt); sukkersyge eller forværring af sukkersyge, af og til ledsaget af syreforgiftning (ketoacidose - ketonstoffer i blod og urin) eller bevidstløshed; krampeanfald, sædvanligvis hos patienter med tidligere krampeanfald (epilepsi); muskelstivhed eller muskelkramper (inklusive øjenbevægelser); restless legs-syndrom (stærk uro i underbenene); problemer med at tale; stammen; langsom hjertefrekvens (puls); følsomhed over for sollys; næseblod; udspilet mave; hukommelsestab eller glemsomhed; ufrivillig ufrivillig vandladning (urininkontinens); vandladningsbesvær; hårtab; manglende menstruation eller længere intervaller mellem menstruationerne; brystforandringer hos mænd og kvinder, såsom unormal produktion af brystmælk eller unormal vækst. 
Uncommon side effects (may affect up to 1 in 100 people) include hypersensitivity (e.g. swelling in the mouth and throat, itching, rash); diabetes or the worsening of diabetes, occasionally associated with ketoacidosis (ketones in the blood and urine) or coma; seizures, usually associated with a history of seizures (epilepsy); muscle stiffness or spasms (including eye movements); restless legs syndrome; problems with speech; stuttering; slow heart rate; sensitivity to sunlight; bleeding from the nose; abdominal distension; memory loss or forgetfulness; urinary incontinence; lack of ability to urinate; hair loss; absence or decrease in menstrual periods; and changes in breasts in males and females such as an abnormal production of breast milk or abnormal growth.
Ortostatisk hypotension10 
Vascular disorders Orthostatic hypotension10
Hjælpestof, som behandleren skal være opmærksom på Hver filmovertrukket tablet indeholder 275,5 mg lactose. 
Excipient with known effect Each film-coated tablet contains 275.5 mg lactose.
Olanzapine Teva 5 mg, 10 mg og 15 mg smeltetabletter fås i kartoner med 28, 30, 35, 50, 56, 70 eller 98 tabletter. 
Olanzapine Teva 5 mg, 10 mg and 15 mg orodispersible tablets are available in cartons containing 28, 30, 35, 50, 56, 70 or 98 tablets.
Hver Olanzapine Teva 7,5 mg filmovertrukket tablet indeholder 7,5 mg af det aktive stof. 
Each Olanzapine Teva 7.5 mg film-coated tablet contains 7.5 mg of the active substance.
Dystoni (inklusive okulogyration) Tardiv dyskinesi11 Amnesi9 
Tardive dyskinesia Amnesia9
Hjælpestof, som behandleren skal være opmærksom på Hver filmovertrukket tablet indeholder 137,8 mg lactose. 
Excipient with known effect Each film-coated tablet contains 137.8 mg lactose.
Sådan skal du tage Olanzapine Teva 
How to take Olanzapine Teva
Hjælpestof, som behandleren skal være opmærksom på Hver smeltetablet indeholder 47,5 mg lactose, 0,2625 mg saccharose og 2,25 mg aspartam (E951). 
Each orodispersible tablet contains 47.5 mg lactose, 0.2625 mg sucrose and 2.25 mg aspartame (E951).
QTc-forlængelse blev defineret som Fridericia korrigeret QT (QTcF) ≥ 500 millisekunder (msek) på et hvilket som helst tidspunkt post-baseline hos patienter med baseline QTcF< 500 msek. 
In clinical trials, clinically meaningful QTc prolongations (Fridericia QT correction [QTcF] ≥500 milliseconds [msec] at any time post baseline in patients with baseline QTcF <500 msec) were uncommon (0.1% to 1%) in patients treated with olanzapine, with no significant differences in associated cardiac events compared to placebo.
Artralgi9 
Pyrexia10
• Skizofreni, en lidelse med symptomer såsom: mistro, ualmindelig mistænksomhed og indesluttethed eller at man hører, ser og mærker ting, som ikke eksisterer. 
Olanzapine Teva belongs to a group of medicines called antipsychotics and is used to treat the following conditions: - Schizophrenia, a disease with symptoms such as hearing, seeing or sensing things which are not there, mistaken beliefs, unusual suspiciousness, and becoming withdrawn.
Olanzapine Teva 7,5 mg filmovertrukne tabletter 
Olanzapine Teva 7.5 mg film-coated tablets
Inden du påbegynder behandling med Olanzapine Teva samt jævnligt i løbet af behandlingen skal din læge tage blodprøver for at kontrollere indholdet af sukker og fedt i dit blod. 
Your doctor should do blood tests to check blood sugar and certain fat levels before you start taking Olanzapine Teva and regularly during treatment.
Olanzapine Teva 5 mg smeltetabletter Olanzapine Teva 10 mg smeltetabletter Olanzapine Teva 15 mg smeltetabletter Olanzapine Teva 20 mg smeltetabletter 
Olanzapine Teva 5 mg orodispersible tablets Olanzapine Teva 10 mg orodispersible tablets Olanzapine Teva 15 mg orodispersible tablets Olanzapine Teva 20 mg orodispersible tablets
Hjælpestof, som behandleren skal være opmærksom på Hver filmovertrukket tablet indeholder 71,3 mg lactose. 
Excipient with known effect Each film-coated tablet contains 71.3 mg lactose.
Olanzapine Teva 7,5 mg filmovertrukne tabletter Hver filmovertrukket tablet indeholder 7,5 mg olanzapin. 
Olanzapine Teva 7.5 mg film-coated tablets Each film-coated tablet contains 7.5 mg olanzapine.
Olanzapine Teva 20 mg filmovertrukne tabletter Hver filmovertrukket tablet indeholder 20 mg olanzapin. 
Olanzapine Teva 20 mg film-coated tablets Each film-coated tablet contains 20 mg olanzapine.
op til (≥ 1,467 mmol/l). 
(≥ 1.016 mmol/l-<1.467 mmol/l) to high (≥1.467 mmol/l).
På trods af dette bør alle mulige risikofaktorer for venøse tromboembolier identificeres, f.eks. immobilisation og forebyggende foranstaltninger iværksættes, da patienter, som lider af skizofreni, ofte har sygdomsbetingede risikofaktorer for venøse tromboembolier. 
However, since patients with schizophrenia often present with acquired risk factors for venous thromboembolism all possible risk factors of VTE, e.g. immobilisation of patients, should be identified and preventive measures undertaken.
Hjælpestof, som behandleren skal være opmærksom på Hver smeltetablet indeholder 95,0 mg lactose, 0,525 mg saccharose og 4,5 mg aspartam (E951). 
Each orodispersible tablet contains 95.0 mg lactose, 0.525 mg sucrose and 4.5 mg aspartame (E951).
Erektil dysfunktion hosmænd 
Cardiac disorders
Forbigående, asymptomatisk forhøjede leveraminotransfera ser (ALAT, ASAT), særligt initialt i behandlingen (se pkt. 
Hepatobiliary disorders Transient, asymptomatic elevations of hepatic aminotransferases (ALT, AST), especially in early treatment (see section 4.4)
Hver Olanzapine Teva 2,5 mg filmovertrukket tablet indeholder 2,5 mg af det aktive stof. 
Each Olanzapine Teva 2.5 mg film-coated tablet contains 2.5 mg of the active substance.
Olanzapine Teva 2,5 mg filmovertrukne tabletter Olanzapine Teva 5 mg filmovertrukne tabletter Olanzapine Teva 7,5 mg filmovertrukne tabletter Olanzapine Teva 10 mg filmovertrukne tabletter Olanzapine Teva 15 mg filmovertrukne tabletter Olanzapine Teva 20 mg filmovertrukne tabletter 
Olanzapine Teva 2.5 mg film-coated tablets Olanzapine Teva 5 mg film-coated tablets Olanzapine Teva 7.5 mg film-coated tablets Olanzapine Teva 10 mg film-coated tablets Olanzapine Teva 15 mg film-coated tablets Olanzapine Teva 20 mg film-coated tablets
De hyppigst rapporterede (set hos ≥ 1 % af patienter) bivirkninger, som blev set i forbindelse med anvendelse af olanzapin i kliniske forsøg, var døsighed og vægtøgning, eosinofili, forhøjede niveauer af prolaktin, kolesterol, glucose og triglycerider (se pkt. 
The most frequently (seen in ≥1% of patients ) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema.
Malignt neuroleptikasyndro m12 (se pkt. 
Neuroleptic malignant syndrome (see section 4.4)12
Hver Olanzapine Teva 20 mg filmovertrukket tablet indeholder 20 mg af det aktive stof. 
Each Olanzapine Teva 20 mg film-coated tablet contains 20 mg of the active substance.
Olanzapine Teva 2,5 mg filmovertrukne tabletter Olanzapine Teva 5 mg filmovertrukne tabletter Olanzapine Teva 7,5 mg filmovertrukne tabletter Olanzapine Teva 10 mg filmovertrukne tabletter Olanzapine Teva 15 mg filmovertrukne tabletter Olanzapine Teva 20 mg filmovertrukne tabletter olanzapin 
Olanzapine Teva 2.5 mg film-coated tablets Olanzapine Teva 5 mg film-coated tablets Olanzapine Teva 7.5 mg film-coated tablets Olanzapine Teva 10 mg film-coated tablets Olanzapine Teva 15 mg film-coated tablets Olanzapine Teva 20 mg film-coated tablets Olanzapine
Det skal du vide, før du begynder at tage Olanzapine Teva Tag ikke Olanzapine Teva: 
What you need to know before you take Olanzapine Teva 3.
Olanzapine Teva 2,5 mg filmovertrukne tabletter Hver filmovertrukket tablet indeholder 2,5 mg olanzapin. 
Olanzapine Teva 2.5 mg film-coated tablets Each film-coated tablet contains 2.5 mg olanzapine.
Hver Olanzapine Teva 20 mg smeltetablet indeholder 20 mg af det aktive stof. 
Each Olanzapine Teva 20 mg orodispersible tablet contains 20 mg of the active substance.
Olanzapine Teva 20 mg filmovertrukket tablet er en lyserød, bikonveks, oval filmovertrukket tablet, præget med ”OL 20” på den ene side og glat på den anden side. 
Olanzapine Teva 20 mg film-coated tablet is a pink, biconvex, oval film-coated tablet, debossed ”OL 20” on one side and plain on the other.
Hver Olanzapine Teva 10 mg smeltetablet indeholder 10 mg af det aktive stof. 
Each Olanzapine Teva 10 mg orodispersible tablet contains 10 mg of the active substance.
Olanzapine Teva 7,5 mg filmovertrukket tablet er en hvid, bikonveks, rund filmovertrukket tablet, præget med ”OL 7,5” på den ene side og glat på den anden side. 
Olanzapine Teva 7.5 mg film-coated tablet is a white, biconvex, round film-coated tablet, debossed ”OL 7.5” on one side and plain on the other.
Olanzapine Teva 10 mg filmovertrukne tabletter Hver filmovertrukket tablet indeholder 10 mg olanzapin. 
Olanzapine Teva 10 mg film-coated tablets Each film-coated tablet contains 10 mg olanzapine.
Olanzapine Teva 20 mg filmovertrukne tabletter 
Olanzapine Teva 20 mg film-coated tablets
Olanzapine Teva 5 mg filmovertrukne tabletter Hver filmovertrukket tablet indeholder 5 mg olanzapin. 
Olanzapine Teva 5 mg film-coated tablets Each film-coated tablet contains 5 mg olanzapine.
Undersøgelsen omfattede 1.481 patienter med varierende grad af hertil forbundne depressive symptomer (middelværdi før behandling lig 16,6 ved Montgomery-Asberg Depression Rating Scale). 
In a multinational, double-blind, comparative study of schizophrenia, schizoaffective, and related disorders which included 1,481 patients with varying degrees of associated depressive symptoms (baseline mean of 16.6 on the Montgomery-Asberg Depression Rating Scale), a prospective secondary analysis of baseline to endpoint mood score change demonstrated a statistically significant improvement (p= 0.001) favouring olanzapine (-6.0) versus haloperidol (-3.1).
Olanzapine Teva 20 mg smeltetabletter fås i kartoner med 28, 30, 35, 56, 70 eller 98 tabletter. 
Olanzapine Teva 20 mg orodispersible tablets are available in cartons containing 28, 30, 35, 56, 70 or 98 tablets.
Hver Olanzapine Teva 10 mg filmovertrukket tablet indeholder 10 mg af det aktive stof. 
Each Olanzapine Teva 10 mg film-coated tablet contains 10 mg of the active substance.
Olanzapine Teva 20 mg filmovertrukne tabletter EU/1/07/427/020 - 28 tabletter pr. karton. 
Olanzapine Teva 20 mg film-coated tablets EU/1/07/427/020 - 28 tablets, per box
Olanzapine Teva 15 mg filmovertrukne tabletter fås i kartoner med 28, 30, 35, 50, 56, 70 eller 98 filmovertrukne tabletter. 
Olanzapine Teva 15 mg film-coated tablets are available in cartons of 28, 30, 35, 50, 56, 70 or 98 filmcoated tablets.
Olanzapine Teva 2,5 mg filmovertrukne tabletter EU/1/07/427/001 - 28 tabletter pr. karton. 
Olanzapine Teva 2.5 mg film-coated tablets EU/1/07/427/001 - 28 tablets, per box
Din læge vil fortælle dig, hvor mange Olanzapine Teva tabletter, du skal tage og i hvor lang tid, du skal tage dem. Dagsdosis for Olanzapine Teva er mellem 5 mg og 20 mg. Konsulter din læge, hvis dine symptomer vender tilbage, men stop ikke med at tage Olanzapine Teva medmindre, at din læge siger det. 
Consult your doctor if your symptoms return but do not stop taking Olanzapine Teva unless your doctor tells you to.
7 filmovertrukne tabletter 7 x 1 filmovertrukne tabletter 28 filmovertrukne tabletter 28 x 1 filmovertrukne tabletter 30 filmovertrukne tabletter 30 x 1 filmovertrukne tabletter 35 filmovertrukne tabletter 35 x 1 filmovertrukne tabletter 50 filmovertrukne tabletter 50 x 1 filmovertrukne tabletter 56 filmovertrukne tabletter 56 x 1 filmovertrukne tabletter 60 filmovertrukne tabletter 70 filmovertrukne tabletter 70 x 1 filmovertrukne tabletter 98 filmovertrukne tabletter 98 x 1 filmovertrukne tabletter 
7 film-coated tablets 7 x 1 film-coated tablets 28 film-coated tablets 28 x 1 film-coated tablets 30 film-coated tablets 30 x 1 film-coated tablets 35 film-coated tablets 35 x 1 film-coated tablets 50 film-coated tablets 50 x 1 film-coated tablets 56 film-coated tablets 56 x 1 film-coated tablets 60 film-coated tablets 70 film-coated tablets 70 x 1 film-coated tablets 98 film-coated tablets 98 x 1 film-coated tablets
Olanzapine Teva 15 mg filmovertrukket tablet er en lyseblå, bikonveks, oval filmovertrukket tablet, præget med ”OL 15” på den ene side og glat på den anden side. 
Olanzapine Teva 15 mg film-coated tablet is a light blue, biconvex, oval film-coated tablet, debossed ”OL 15” on one side and plain on the other.
Høje niveauer af gammaglutamyltransferase10 
Glutamyltransfera se10
Olanzapine Teva 15 mg filmovertrukne tabletter EU/1/07/427/016 - 28 tabletter pr. karton. 
Olanzapine Teva 15 mg film-coated tablets EU/1/07/427/016 - 28 tablets, per box
Olanzapine Teva 15 mg filmovertrukne tabletter 
Olanzapine Teva 15 mg film-coated tablets
Olanzapine Teva 10 mg filmovertrukne tabletter 
Olanzapine Teva 10 mg film-coated tablets
Olanzapine Teva 2,5 mg filmovertrukne tabletter fås i kartoner med 28, 30, 35, 56, 70 eller 98 filmovertrukne tabletter. 
Olanzapine Teva 2.5 mg film-coated tablets are available in cartons of 28, 30, 35, 56, 70 or 98 filmcoated tablets.
28 filmovertrukne tabletter 28 x 1 filmovertrukne tabletter 30 filmovertrukne tabletter 30 x 1 filmovertrukne tabletter 35 filmovertrukne tabletter 35 x 1 filmovertrukne tabletter 50 filmovertrukne tabletter 50 x 1 filmovertrukne tabletter 56 film-coated tablets 56 x 1 filmovertrukne tabletter 70 filmovertrukne tabletter 70 x 1 filmovertrukne tabletter 98 filmovertrukne tabletter 98 x 1 filmovertrukne tabletter 
28 film-coated tablets 28 x 1 film-coated tablets 30 film-coated tablets 30 x 1 film-coated tablets 35 film-coated tablets 35 x 1 film-coated tablets 50 film-coated tablets 50 x 1 film-coated tablets 56 film-coated tablets 56 x 1 film-coated tablets 70 film-coated tablets 70 x 1 film-coated tablets 98 film-coated tablets 98 x 1 film-coated tablets
Hver Olanzapine Teva 15 mg filmovertrukket tablet indeholder 15 mg af det aktive stof. 
Each Olanzapine Teva 15 mg film-coated tablet contains 15 mg of the active substance.
Olanzapine Teva 20 mg smeltetabletter EU/1/07/427/035 - 28 tabletter pr. karton. 
Olanzapine Teva 20 mg orodispersible tablets EU/1/07/427/035 - 28 tablets, per box
Olanzapine Teva 2,5 mg filmovertrukket tablet er en hvid, bikonveks, rund filmovertrukket tablet, præget med ”OL 2,5” på den ene side og glat på den anden side. 
Olanzapine Teva 2.5 mg film-coated tablet is a white, biconvex, round film-coated tablet, debossed ”OL 2.5” on one side and plain on the other.
Det skal du vide, før du begynder at tage Olanzapine Teva Sådan skal du tage Olanzapine Teva Bivirkninger 
What you need to know before you take Olanzapine Teva
Olanzapine Teva 20 mg filmovertrukne tabletter OPA/Aluminium/PVC-Aluminium blister i kartoner a 28, 30, 35, 56, 70 eller 98 filmovertrukne tabletter pr. karton. 
Olanzapine Teva 20 mg film-coated tablets OPA/alu/PVC-alu blisters in cartons of 28, 30, 35, 56, 70 or 98 film-coated tablets per carton.
Olanzapine Teva 2,5 mg filmovertrukne tabletter OPA/Aluminium/PVC-Aluminium blister i kartoner a 28, 30, 35, 56, 70 eller 98 filmovertrukne tabletter pr. karton. 
Olanzapine Teva 2.5 mg film-coated tablets OPA/alu/PVC-alu blisters in cartons of 28, 30, 35, 56, 70 and 98 film-coated tablets per carton.
Hver Olanzapine Teva 5 mg filmovertrukket tablet indeholder 5 mg af det aktive stof. 
Each Olanzapine Teva 5 mg film-coated tablet contains 5 mg of the active substance.
14 Observerede normalniveauer ved faste ved baseline (< 1,016 mmol/l, som steg til (≥ 1,467 mmol/l) 
14 Observed for fasting normal levels at baseline (<1.016 mmol/l) which increased to high
28 filmovertrukne tabletter 30 filmovertrukne tabletter 35 filmovertrukne tabletter 56 filmovertrukne tabletter 70 filmovertrukne tabletter 98 filmovertrukne tabletter 
28 film-coated tablets 30 film-coated tablets 35 film-coated tablets 56 film-coated tablets 70 film-coated tablets 98 film-coated tablets
Glucosuria 
Olanzapine
- Øvrige indholdstoffer: (tabletkernen) lactosemonohydrat, hydroxypropylcellulose, crospovidon (type A), silica, kolloid vandfri, mikrokrystallinsk cellulose, magnesiumstearat, (tabletovertrækket) hypromellose, polydextose, glyceroltriacetat, macrogol 8000, titandioxid (E171). 
Tablet core: lactose monohydrate, hydroxypropylcellulose, crospovidone (type A), silica colloidal anhydrous, microcrystalline cellulose, magnesium stearate.
Olanzapine Teva 20 mg smeltetabletter 
Olanzapine Teva 20 mg orodispersible tablets
Olanzapine Teva 10 mg filmovertrukket tablet er en hvid, bikonveks, rund filmovertrukket tablet, præget med ”OL 10” på den ene side og glat på den anden side. 
Olanzapine Teva 10 mg film-coated tablet is a white, biconvex, round film-coated tablet, debossed ”OL 10” on one side and plain on the other.
Olanzapine Teva 5 mg filmovertrukne tabletter 
Olanzapine Teva 5 mg film-coated tablets
Hver Olanzapine Teva 15 mg smeltetablet indeholder 15 mg af det aktive stof. 
Each Olanzapine Teva 15 mg orodispersible tablet contains 15 mg of the active substance.
Olanzapine Teva 10 mg smeltetabletter 
Olanzapine Teva 10 mg orodispersible tablets
Olanzapine Teva 10 mg smeltetabletter EU/1/07/427/027 - 28 tabletter pr. karton. 
Olanzapine Teva 10 mg orodispersible tablets EU/1/07/427/027 - 28 tablets, per box
Olanzapine Teva 5 mg smeltetabletter EU/1/07/427/023 - 28 tabletter pr. karton. 
Olanzapine Teva 5 mg orodispersible tablets EU/1/07/427/023 - 28 tablets, per box
• Blodpropper i venerne (en ikke almindelig bivirkning, som forekommer hos op til 1 ud af 100 patienter), særligt i benene (symptomerne omfatter hævelse og smerte i benet samt hudrødme). 
Tell your doctor immediately if you have: - unusual movement (a common side effect that may affect up to 1 in 10 people) mainly of the face or tongue; - blood clots in the veins (an uncommon side effect that may affect up to 1 in 100 people) especially in the legs (symptoms include swelling, pain, and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing.
Olanzapine Teva 20 mg smeltetabletter Olanzapin 
NAME OF THE MEDICINAL PRODUCT Olanzapine Teva 20 mg orodispersible tablets Olanzapine
Hver Olanzapine Teva 5 mg smeltetablet indeholder 5 mg af det aktive stof. 
Each Olanzapine Teva 5 mg orodispersible tablet contains 5 mg of the active substance.
EU/1/07/427/028 - 30 tabletter pr. karton. 
EU/1/07/427/028 - 30 tablets, per box
• Slagtilfælde eller forbigående symptomer på slagtilfælde 
Hepatobiliary disorders Transient, asymptomatic elevations of hepatic
28 filmovertrukne tabletter 30 filmovertrukne tabletter 35 filmovertrukne tabletter 50 filmovertrukne tabletter 56 filmovertrukne tabletter 70 filmovertrukne tabletter 98 filmovertrukne tabletter 
28 film-coated tablets 30 film-coated tablets 35 film-coated tablets 50 film-coated tablets 56 film-coated tablets 70 film-coated tablets 98 film-coated tablets
Olanzapine Teva 15 mg smeltetabletter EU/1/07/427/031 - 28 tabletter pr. karton. 
Olanzapine Teva 15 mg orodispersible tablets EU/1/07/427/031 - 28 tablets, per box
EU/1/07/427/036 - 30 tabletter pr. karton. 
EU/1/07/427/036 - 30 tablets, per box
EU/1/07/427/017 - 30 tabletter pr. karton. 
EU/1/07/427/017 - 30 tablets, per box
EU/1/07/427/048 - 70 tabletter pr. karton. 
EU/1/07/427/048 - 70 tablets, per box
Olanzapine Teva 20 mg filmovertrukne tabletter fås i kartoner med 28, 30, 35, 56, 70 eller 98 filmovertrukne tabletter. 
Olanzapine Teva 20 mg film-coated tablets are available in cartons of 28, 30, 35, 56, 70 or 98 filmcoated tablets.
I de kliniske forsøg var klinisk betydningsfulde QTc-forlængelser usædvanlige (0,1 % til 1 %) hos de patienter, som blev behandlet med olanzapin. 
≥500 milliseconds [msec] at any time post baseline in patients with baseline QTcF <500 msec) were uncommon (0.1% to 1%) in patients treated with olanzapine, with no significant differences in associated cardiac events compared to placebo.
EU/1/07/427/029 - 50 tabletter pr. karton. 
EU/1/07/427/029 - 50 tablets, per box